Medical device company MediPines Corporation stated on Friday that it has received US FDA 510(k) clearance for the ground-breaking portable MediPines Gas Exchange Monitor respiratory device for freedivers to provide real-time, clinically actionable data in oxygen deficit.

The company added that freedivers place themselves in extreme conditions, which push the outer limits of human lung physiology and can lead to high oxygen deficit.

According to the company, the MediPines Gas Exchange Monitor device provided rapid feedback to the research team tasked with assessing the freedivers' gas exchange status. The oxygen deficit was developed for detecting gas exchange inefficiency using a simple, non-invasive method. The physiological demands placed on the athletes are tremendous.

This breakthrough technology is transforming the approach to measuring pulmonary gas exchange in a wide variety of clinical settings, relevant for the 33 million patients in the US (350m globally), who suffer from respiratory disease, disclosed the company.

Additionally, the novel physiologic results on world elite freedivers' using the company' non-invasive MediPines Gas Exchange Monitor were presented at the Experimental Biology 2019 conference. Dr Philip Ainslie, co-director of the Centre for Heart, Lung and Vascular Health at the University of British Columbia, conducted the study in Split, Croatia.